Who is sponsoring NCT06727890?

NCT06727890 is sponsored by Qilu Hospital of Shandong University.

What drugs are being tested in NCT06727890?

Interventions in NCT06727890: Danshen Dripping Pill, Placebo.

What condition does NCT06727890 study?

NCT06727890 studies Diabetic Microvascular Angina.

Is NCT06727890 still recruiting?

NCT06727890 is currently not yet recruiting. Last updated 11 December 2024.

Last reviewed 2024-12-11 · How we verify

NCT06727890: MVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compound Danshen Dripping Pill for Diabetic Microvascular Angina

Not yet recruiting Phase 4 Last updated 11 December 2024

What this trial tests

Phase 4 trial testing Danshen Dripping Pill in Diabetic Microvascular Angina in 162 participants. Not yet recruiting.

Timeline

1 January 2025

Primary endpoint
31 December 2026

30 June 2027

Quick facts

Lead sponsor	Qilu Hospital of Shandong University
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	162
Start date	1 January 2025
Primary completion	31 December 2026
Estimated completion	30 June 2027
Sites	3 locations across China

Drugs / interventions tested

Danshen Dripping Pill — full drug profile →
Placebo

Conditions studied

Diabetic Microvascular Angina — all drugs for Diabetic Microvascular Angina →

Sponsor

Qilu Hospital of Shandong University

Who can join

18 and older, any sex, with Diabetic Microvascular Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy and safety of Compound Danshen Dripping Pill in patients with diabetic microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Compound Danshen Dripping Pill on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06727890 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
Last refreshed: 11 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06727890.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing